The financing removes near-term cash runway risk and funds critical Phase 3 catalysts, but the massive dilution will pressure the stock. Watch for the pathological complete response data trigger (≥50 patients) that accelerates Series B warrant expiration — early positive data could reduce overhang. The board designation by Commodore adds activist-like oversight, potentially improving governance.
Price Chart
Executive Summary
Agenus entered into a securities purchase agreement for a ~$85M PIPE financing led by Commodore Capital, issuing shares at $3.69 along with Series A ($4.02 strike) and Series B ($5.03 strike) warrants. Proceeds will fund the Phase 3 neoadjuvant trial of botensilimab/balstilimab in colon cancer and extend operating runway through key readouts. The offering is highly dilutive relative to the $140M market cap, but the cash infusion and board designation rights for Commodore provide a governance backstop.
Key Financial Metrics
Key Facts
- ~$85M PIPE priced at $3.69 per share (with warrants), plus pre-funded warrants at $3.68
- Series A warrants exercisable at $4.02; Series B warrants at $5.03
- Series A warrants expire 30 days after 60 patients dosed in Phase 3 colon cancer trial; Series B warrants expire 30 days after pathologic response data for ≥50 patients
- Lead investor Commodore Capital Master LP receives board designation rights (two directors) upon reaching 5% beneficial ownership
- Proceeds used for general corporate purposes and to extend runway through pCR, interim EFS, and final EFS readouts for BOT/BAL in colon cancer
- 90-day lockup on further equity issuance without lead investor consent
- Company to use commercially reasonable efforts to extend $24.75M promissory note maturity with Ocean 1181 LLC
Financial Impact
~$85M gross proceeds; dilution of approximately 61% of pre-offering market cap from shares and pre-funded warrants, with additional potential dilution from Series A and B warrants
Risk Factors
- Significant dilution from the offering and warrants could weigh on share price
- Clinical trial risk: BOT/BAL Phase 3 colon cancer data may fail to meet endpoints
- Potential need for additional financing if trial readouts are delayed or negative
- Warrant overhang: Series A and B warrants could be exercised, adding further dilution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-301414 |
| Document: d111026dex102.htm | 0001193125-26-301414 |
| Document: d111026dex43.htm | 0001193125-26-301414 |
| Document: d111026dex42.htm | 0001193125-26-301414 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 13, 2026 7w ago | 8-K | $7.00 $6.94 | ▼ −0.86% | ▲ +0.89% | $8.32 (+18.86%) |
Aug 12, 2026 7w ago | Institutional Cluster | $6.90 $6.89 | ▼ −0.14% | ▲ +1.75% | $8.32 (+20.58%) |
Aug 7, 2026 7w ago | S-3 | $7.00 $7.76 | ▼ −10.87% | ▼ −11.78% | $8.32 (−18.86%) |
Aug 6, 2026 8w ago | 8-K | $7.49 $8.24 | ▲ +10.01% | ▲ +9.41% | $8.32 (+11.08%) |
Jul 18, 2026 10w ago | S-3 | $4.97 $7.15 | ▼ −43.86% | ▼ −39.74% | $8.32 (−67.40%) |
Jul 13, 2026 11w ago | 8-K | $6.12 $7.00 | ▼ −14.38% | ▼ −11.19% | $8.32 (−35.95%) |
May 13, 2026 20w ago | DEFA14A | $3.47 $3.39 | ▼ −2.31% | ▼ −1.69% | $8.32 (+139.77%) |
May 11, 2026 20w ago | 8-K | $3.26 $3.11 | ▼ −4.60% | ▼ −4.30% | $8.32 (+155.21%) |
Dec 4, 2025 43w ago | Court Ruling | $4.06 $3.22 | ▲ +20.69% | ▲ +21.18% | $8.32 (−104.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access